Garadacimab (also known as CSL312) is a medication being studied for the treatment of Hereditary Angioedema (HAE). It is designed to prevent HAE attacks in patients who are currently using other preventive treatments. This medication works by targeting specific proteins in the body that are involved in causing swelling episodes in HAE patients.

Plasma-derived C1 inhibitor (pdC1INH) is a medication made from human blood plasma that helps prevent swelling attacks in people with HAE. It works by replacing the missing or malfunctioning C1 inhibitor protein in patients with HAE.

Kallikrein inhibitors (KK inhibitors) are medications that work by blocking a specific protein called kallikrein, which is involved in causing swelling in HAE patients. These medications help prevent HAE attacks by reducing the activity of this protein in the body.

Hereditary Angioedema (HAE) – A rare genetic condition that causes sudden episodes of swelling in various parts of the body, including the hands, feet, face, intestinal walls, and airways. The swelling occurs because of a problem with a blood protein called C1 inhibitor, which normally helps regulate blood vessel function. Episodes of swelling can happen spontaneously or be triggered by stress, injury, or certain medications. The swelling typically develops slowly over several hours and can last for a few days. During an attack, the affected area may feel stretched, painful, and warm to the touch. Between episodes, people with HAE typically have no visible signs of the condition.